Markets
BSE See
NSE See
28,114.56
409.21 (1.48%)

US FDA’s Alert On Wockhardt: Much Ado About Nothing?

| 5/30/2013 9:02 PM Thursday

Pharma giant Wockhardt has received a strong setback after the US FDA sounded an alert on its Waluj manufacturing facility, after which the stock was hammered by more than 25 per cent in just two trading sessions. The market, however, seems to be overreacting to these developments. Shrikant Akolkar tells us more.

One of the worst things to happen to any stock is for it to get hit by factors which are apparently serious but on deeper exploration seem to be routine. This happens chiefly due to investors’ knee-jerk reaction to news flows which creates humongous negativity around it. One company which has recently been hit by this syndrome is Wockhardt.

We had recommended Wockhardt in DSIJ Vol. 28, Issue # 9 (dated 21 April, 2013) in our cover story ‘Cherry Picking’. The scrip was severely hammered following the recent US FDA alert on its manufacturing facility located in Waluj, Aurangabad district of Maharashtra. In just two trading sessions alone (May 23 and 24, 2013) it lost more than 25 per cent in value. Currently, the stock is down 35 per cent from where we had recommended it. Investors who have acted on our advice would surely be jittery in the wake of such a slide in the stock’s price. What should their future course in this counter be? Should one sell and book losses or wait out the depression? Here are the answers that you would be looking out for.

To start with, the hammering of the stock was a knee-jerk reaction arising out of fears fuelled by a particular event. This fear was accentuated by many other factors that were external to the company. The principal factor among these was the developments in Ranbaxy earlier in the same week.

Ranbaxy, the pharma company now owned by Daichhi Sankyo, pleaded guilty before the United States Department of Justice on compliance related issues in two of its manufacturing facilities. This was in any case weighing heavily on pharma stocks. The alert on Wockhardt’s Waluj facility came immediately after this, and dampened the sentiment on the stock.

What is worth noting is that Ranbaxy had ignored earlier malpractices, the consequences of which it had to bear. Wockhardt, however, had invited the US FDA team to audit its new injectables unit at Waluj. This is what differentiates between the two companies.

Find More Articles on: DSIJ Magazine, Special Report, Stock Recommendations, Fundamental Picks, Product, Large Cap

«« First « Previous |1 2 | Last ››
collapse Related Readings collapse

DSIJ
Mindshare

Bulls Back On D-Street, Bankex On Upper Hand

Bulls Back On D-Street, Bankex On Upper Hand

The Indian markets witnessed a handsome move in today’s session. Majority of the sectoral indices recovered well. Bankex stocks were leading today’s rally, and index surges around 354 points. This was followed by Auto and Healthcare index, as they were also surges more than 300 points each.  The Nifty closed above major resistance level and was up by 111 point and closed at 8532 while Sensex was up by 409 point in today’s trading session and closed at 28114.

Gati's Net Profit tanks by 35.34 per cent in the June 2015 quarter

Gati's Net Profit tanks by 35.34 per cent in the June 2015 quarter

Gati declared financial results of June 2015 quarter. The company's total income from operations increased by 4.68 per cent amounting to Rs 416.24 crore in Q1FY16 as compared to same period in previous financial year. 

ITC Posts good Q1 result

ITC Posts good Q1 result

Recently, ITC announced its First Quarter FY16 result, the total revenue declined by 7.14 per cent to Rs 8587.7 crore compared to Rs 9248.29 crore year on year basis. FMCG-Others Segment registers revenue growth of 12.2 per cent amidst subdued demand conditions.

Petronet LNG Net Increases By 58% As Prabhat Singh Appointed As MD

Gail’s Director Marketing Prabhat Singh has been appointed as the MD and CEO of Petronet LNG. This post has been vacated by Dr. AK Balyan, whose tenure ended on July 16 2015.

Maggi ban pushes Nestle first time into loss in more than two decades

Maggi ban pushes Nestle first time into loss in more than two decades

The FMCG company Nestle India (NESTLEIND) announced its unaudited results on July 29 2015, for the second quarter as the half year ended on June 30 2015. The company reported a net loss of Rs 64.4 crore for the Q2CY15, as compared to a net profit of Rs 320.28 crore in Q1CY15. The company has been faced with a very unusual situation after the ban on its flagship product Maggi noodles during the quarter.

Index Trends And Stocks In Action July 31, 2015

Index Trends And Stocks In Action July 31, 2015

The Indian Equity Market continued its winning streak from the second successive session positive sentiments from the global market and short covering got the bulls progressing.

Market Likely To Open Flat To Positive

Market Likely To Open Flat To Positive

A SGX CNX Nifty Index future for July delivery was up 15.5 points at 8,488. Indian markets likely to open flat to positive. Aarti Drugs, Apcotex Ind, Archies, Cesc, Elgi Equipments, Force Motors, Godfrey Phillips, ICICI Bank, L&T, Shriram Transport Finance, Sun Tv, Tata Global and Titan would be reporting first quarter earnings today.

Indices Bounce Back On F&O Expiry

Indices Bounce Back On F&O Expiry

The Indian markets witnessed a good up-move in the last session of July F&O series expiry. The Sensex ended 141 points higher at 27705 while Nifty ended 46 points above its previous closing at 8421.

Wabco India's Net Profit jumps by 54.92 per cent in Q1FY16

Wabco India's Net Profit jumps by 54.92 per cent in Q1FY16

Wabco India (WIL) announced June 2015 quarter results. The company's revenue increased by 18.99 per cent to Rs 385 crore in Q1FY16 as compared to same period in previous financial year. 

Mphasis Net Profit slides by 12 per cent to Rs 156 crore in Q1

Mphasis Net Profit slides by 12 per cent to Rs 156 crore in Q1

Yesterday Mphasis announced its financial results for the first quarter ending 30th June 2015. Consolidated net revenues grew by 4.7 per cent to Rs 1496.41 crore as against Rs 1429.03 crore sequentially on a reported basis and net of rupee depreciation grew by 2.6 per cent in Q1 FY16.

Subscribe to
Newsletter

news letter

More for the early bird.

Get the pre-market reports and breakfast news right in your inbox. See latest »

Market
CHIT CHAT

What is your view on markets today?

500  Characters Remaining.
Please LOGIN  to post your comments or Click here to go back.
Rishi Chugh Aug 02 01:35PM
i want any chocolets. plz gime 1. k .
Avinash Shinde Aug 01 10:31PM
Click on demo link above ..
Jatinder singh Aug 01 09:10PM
I am new how I start
bennuri sudhakar Aug 01 06:26PM
va tech buy chance get good returns
tabish ahmed Aug 01 06:06PM
Pls anybody tell me what to do in this